Alpek Q2 2026 slides: EBITDA surges 300%, guidance raised sharply

Alpek’s Q2 2026 results drove a major earnings and balance-sheet upgrade: reported EBITDA jumped 300% to $407M (comparable EBITDA +169% to $336M), while operating free cash flow reached $127M and net debt fell $103M to $1,664M (net debt/EBITDA improved to 2.2x from 3.9x). The company raised full-year 2026 comparable EBITDA guidance to $750–800M (vs. $450–550M previously) and operating free cash flow to $300–350M (vs. $100–150M), supported by higher reference margins tied to Middle East/Red Sea supply disruptions. Management also increased capex to $150M and indicated no dividend resumption in 2026, prioritizing deleveraging and investment.

Analysis

The market is paying for scarcity, not just execution. Alpek’s edge right now is that it sits on the right side of regional dislocation: when imports are unreliable, domestic resin supply earns a premium and utilization snaps higher faster than global peers can respond. That creates a second-order winner in local converters and packaging customers that need continuity more than the cheapest molecule, while global commodity producers lose pricing discipline once shipping routes normalize.

The key risk is that a meaningful share of the quarter looks cyclical and partially reversible. The company already assumes normalization in the back half, so the next 1-3 months are really about whether freight, conflict-driven supply tightness, and inventory gains persist; a de-escalation in the Middle East, smoother Red Sea routing, or a drop in China PET/PP benchmarks would compress margins quickly. Over 6-18 months, the ceiling is global petrochemical overcapacity, which should cap multiple expansion even if cash flow stays strong.

Contrarianly, the balance-sheet inflection may matter more than the headline EBITDA print. Getting leverage closer to target reduces credit risk and could tighten spreads on the 2029-2031 stack, which would support equity duration, but that is a slower catalyst than the market’s immediate excitement. If management cannot show that normalized H2 margins remain comfortably above pre-shock levels, this becomes a cash-generation story rather than a sustained rerating story.

Key Decisions for Investors

• Buy ALPKF only on a 5-8% pullback over the next 2-4 weeks; target a 10-15% move if H2 comparable EBITDA remains above the midpoint and net leverage trends toward 2.0x-2.5x. Falsifier: any guide-down in margins/FCF or a sharp reversal in freight/benchmark spreads.
• Pair trade: long ALPKF / short LYB for 1-3 months to express regional supply-premium versus global commodity exposure. The trade works if domestic pricing power persists while broader petrochemical spreads normalize; cover if LYB margins stabilize and Alpek’s spot premium fades.
• Set a credit watch on Alpek bonds and refinancing spreads for the next 1-2 quarters. If 2029-2031 paper tightens materially and rating outlooks improve, add to equity; if spreads widen despite strong EBITDA, treat the deleveraging narrative as brittle.
• Do not chase the stock at highs; use strength to trim into the print if the market is already assuming the full year guide. The asymmetry is better on pullbacks than on momentum continuation unless geopolitics deteriorate further.